Reviewing Spectrum Pharmaceuticals (NASDAQ:SPPI) & Nabriva Therapeutics AG (NBRV)

Spectrum Pharmaceuticals (NASDAQ: SPPI) and Nabriva Therapeutics AG (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Volatility & Risk

Spectrum Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics AG has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.

Earnings & Valuation

This table compares Spectrum Pharmaceuticals and Nabriva Therapeutics AG’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Spectrum Pharmaceuticals $132.03 million 5.49 -$44.85 million ($0.99) -9.32
Nabriva Therapeutics AG $6.01 million 4.53 -$58.77 million ($2.45) -4.08

Spectrum Pharmaceuticals has higher revenue and earnings than Nabriva Therapeutics AG. Spectrum Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics AG, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Spectrum Pharmaceuticals and Nabriva Therapeutics AG, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spectrum Pharmaceuticals 0 0 4 0 3.00
Nabriva Therapeutics AG 0 0 6 0 3.00

Spectrum Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 8.34%. Nabriva Therapeutics AG has a consensus target price of $16.00, suggesting a potential upside of 60.00%. Given Nabriva Therapeutics AG’s higher probable upside, analysts clearly believe Nabriva Therapeutics AG is more favorable than Spectrum Pharmaceuticals.

Profitability

This table compares Spectrum Pharmaceuticals and Nabriva Therapeutics AG’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spectrum Pharmaceuticals -59.33% -30.95% -16.67%
Nabriva Therapeutics AG N/A -90.54% -72.82%

Institutional and Insider Ownership

66.6% of Spectrum Pharmaceuticals shares are held by institutional investors. Comparatively, 56.7% of Nabriva Therapeutics AG shares are held by institutional investors. 13.3% of Spectrum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Spectrum Pharmaceuticals beats Nabriva Therapeutics AG on 8 of the 12 factors compared between the two stocks.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

What are top analysts saying about Spectrum Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spectrum Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit